Cargando…

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

SIMPLE SUMMARY: Effective anti-infective strategies are of crucial importance in patients with multiple myeloma undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). We compare, for the first time, antibiotic prophylaxis versus granulocyte-colony stimulating facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Eva-Maria, Sauer, Sandra, Klein, Sabrina, Tichy, Diana, Benner, Axel, Bertsch, Uta, Brandt, Juliane, Kimmich, Christoph, Goldschmidt, Hartmut, Müller-Tidow, Carsten, Jordan, Karin, Giesen, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303829/
https://www.ncbi.nlm.nih.gov/pubmed/34298654
http://dx.doi.org/10.3390/cancers13143439
_version_ 1783727183857975296
author Klein, Eva-Maria
Sauer, Sandra
Klein, Sabrina
Tichy, Diana
Benner, Axel
Bertsch, Uta
Brandt, Juliane
Kimmich, Christoph
Goldschmidt, Hartmut
Müller-Tidow, Carsten
Jordan, Karin
Giesen, Nicola
author_facet Klein, Eva-Maria
Sauer, Sandra
Klein, Sabrina
Tichy, Diana
Benner, Axel
Bertsch, Uta
Brandt, Juliane
Kimmich, Christoph
Goldschmidt, Hartmut
Müller-Tidow, Carsten
Jordan, Karin
Giesen, Nicola
author_sort Klein, Eva-Maria
collection PubMed
description SIMPLE SUMMARY: Effective anti-infective strategies are of crucial importance in patients with multiple myeloma undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). We compare, for the first time, antibiotic prophylaxis versus granulocyte-colony stimulating factor (G-CSF) support as anti-infective strategies in this specific setting, including 353 individual cases of HDT/ASCT. We show similar efficacy in preventing infectious complications regarding antibiotic prophylaxis and G-CSF. Furthermore, we demonstrate that G-CSF support is associated with a shorter duration of inpatient stay and a lower rate of emerging multidrug resistant bacteria, especially vancomycin-resistant Enterococcus faecium. Therefore, G-CSF support should be the preferred anti-infective strategy in patients with multiple myeloma receiving HDT/ASCT. ABSTRACT: We compare, in this manuscript, antibiotic prophylaxis versus granulocyte-colony stimulating factor (G-CSF) support as anti-infective strategies, in patients with multiple myeloma (MM), undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). At our institution, antibiotic prophylaxis after HDT/ASCT in MM was stopped in January 2017 and replaced by G-CSF support in March 2017. Consecutive MM patients who received HDT/ASCT between March 2016 and July 2018 were included in this single-center retrospective analysis. In total, 298 patients and 353 individual cases of HDT/ASCT were evaluated. In multivariate analyses, G-CSF support was associated with a significantly shortened duration of severe leukopenia < 1/nL (p < 0.001, hazard ratio (HR) = 16.22), and hospitalization (estimate = −0.19, p < 0.001) compared to antibiotic prophylaxis. Rates of febrile neutropenia, need of antimicrobial therapy, transfer to intensive care unit, and death, were similar between the two groups. Furthermore, antibiotic prophylaxis was associated with a significantly increased risk for the development of multidrug resistant bacteria especially vancomycin-resistant Enterococcus faecium compared to G-CSF support (odds ratio (OR) = 17.38, p = 0.01). Stop of antibiotic prophylaxis as an anti-infective strategy was associated with a reduction in overall resistance rates of bacterial isolates. These results indicate that G-CSF support should be the preferred option in MM patients undergoing HDT/ASCT.
format Online
Article
Text
id pubmed-8303829
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83038292021-07-25 Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Klein, Eva-Maria Sauer, Sandra Klein, Sabrina Tichy, Diana Benner, Axel Bertsch, Uta Brandt, Juliane Kimmich, Christoph Goldschmidt, Hartmut Müller-Tidow, Carsten Jordan, Karin Giesen, Nicola Cancers (Basel) Article SIMPLE SUMMARY: Effective anti-infective strategies are of crucial importance in patients with multiple myeloma undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). We compare, for the first time, antibiotic prophylaxis versus granulocyte-colony stimulating factor (G-CSF) support as anti-infective strategies in this specific setting, including 353 individual cases of HDT/ASCT. We show similar efficacy in preventing infectious complications regarding antibiotic prophylaxis and G-CSF. Furthermore, we demonstrate that G-CSF support is associated with a shorter duration of inpatient stay and a lower rate of emerging multidrug resistant bacteria, especially vancomycin-resistant Enterococcus faecium. Therefore, G-CSF support should be the preferred anti-infective strategy in patients with multiple myeloma receiving HDT/ASCT. ABSTRACT: We compare, in this manuscript, antibiotic prophylaxis versus granulocyte-colony stimulating factor (G-CSF) support as anti-infective strategies, in patients with multiple myeloma (MM), undergoing high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT). At our institution, antibiotic prophylaxis after HDT/ASCT in MM was stopped in January 2017 and replaced by G-CSF support in March 2017. Consecutive MM patients who received HDT/ASCT between March 2016 and July 2018 were included in this single-center retrospective analysis. In total, 298 patients and 353 individual cases of HDT/ASCT were evaluated. In multivariate analyses, G-CSF support was associated with a significantly shortened duration of severe leukopenia < 1/nL (p < 0.001, hazard ratio (HR) = 16.22), and hospitalization (estimate = −0.19, p < 0.001) compared to antibiotic prophylaxis. Rates of febrile neutropenia, need of antimicrobial therapy, transfer to intensive care unit, and death, were similar between the two groups. Furthermore, antibiotic prophylaxis was associated with a significantly increased risk for the development of multidrug resistant bacteria especially vancomycin-resistant Enterococcus faecium compared to G-CSF support (odds ratio (OR) = 17.38, p = 0.01). Stop of antibiotic prophylaxis as an anti-infective strategy was associated with a reduction in overall resistance rates of bacterial isolates. These results indicate that G-CSF support should be the preferred option in MM patients undergoing HDT/ASCT. MDPI 2021-07-09 /pmc/articles/PMC8303829/ /pubmed/34298654 http://dx.doi.org/10.3390/cancers13143439 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Klein, Eva-Maria
Sauer, Sandra
Klein, Sabrina
Tichy, Diana
Benner, Axel
Bertsch, Uta
Brandt, Juliane
Kimmich, Christoph
Goldschmidt, Hartmut
Müller-Tidow, Carsten
Jordan, Karin
Giesen, Nicola
Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title_full Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title_fullStr Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title_full_unstemmed Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title_short Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
title_sort antibiotic prophylaxis or granulocyte-colony stimulating factor support in multiple myeloma patients undergoing autologous stem cell transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303829/
https://www.ncbi.nlm.nih.gov/pubmed/34298654
http://dx.doi.org/10.3390/cancers13143439
work_keys_str_mv AT kleinevamaria antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT sauersandra antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT kleinsabrina antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT tichydiana antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT benneraxel antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT bertschuta antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT brandtjuliane antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT kimmichchristoph antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT goldschmidthartmut antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT mullertidowcarsten antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT jordankarin antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation
AT giesennicola antibioticprophylaxisorgranulocytecolonystimulatingfactorsupportinmultiplemyelomapatientsundergoingautologousstemcelltransplantation